New combo strategy aims to outsmart resistant ovarian cancer
NCT ID NCT05479045
Summary
This study is testing a two-part treatment for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The goal is to see if giving a cancer vaccine first can help a follow-up immunotherapy drug work better and longer by preventing the cancer from becoming resistant. The trial will enroll 24 participants to measure how long the treatment keeps the cancer from growing and to monitor safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.